医学博士，副主任医师。

2018年毕业于北京大学医学部，获肿瘤学博士学位。

主要从事腹膜后肿瘤，软组织肿瘤，结直肠癌肝转移，肝胆胰恶性肿瘤（肝癌，胆管癌，胆囊癌，胰腺癌）的临床诊疗及基础研究。

主持首都卫生发展科研专项基金、CSCO-朝阳肿瘤基金、北京大学学科交叉基金、北京大学肿瘤医院院内基金等多项科研基金项目。

发表SCI论文10余篇。

发表论文

以第一作者（共同第一作者）发表下列文章

1. Wang Z, Wu JH, Lv A, Li CP, Tian XY, Hao CY. Anterior Approach to En Bloc Resection in Left-Sided Retroperitoneal Sarcoma with Adjacent Organ Involvement: A Study of 25 Patients in a Single Center. Med Sci Monit. 2018; 24:961-969.

2. Chengxue H, YanHui G, Nina Z, Zhen W, Teli L, Xiaoxia X, Feng W, Hua Z, Zhi Y, Xianteng Y, Lei X. Construction and Application of a PD-L1-Targeted Multimodal Diagnostic and Dual-Functional Theranostics Nanoprobe. Int J Nanomedicine. 2024; 19.

3. Wang Z, Wu J, Lv A, Tian X, Hao C. En bloc resection for intra-abdominal/retroperitoneal desmoid-type fibromatosis with adjacent organ involvement: A case series and literature review. Biosci Trends. 2018; 12:620-626.

4. Wang Z, Wu J, Lv A, Li C, Li Z, Zhao M, Hao C. Infiltration characteristics and influencing factors of retroperitoneal liposarcoma: Novel evidence for extended surgery and a tumor grading system. Biosci Trends. 2018; 12:185-192.

5. Yao Y, Wang Z, Yong L, Yao Q, Tian X, Wang T, Yang Q, Hao C, Zhou T. Longitudinal and time-to-event modeling for prognostic implications of radical surgery in retroperitoneal sarcoma. CPT Pharmacometrics Syst Pharmacol. 2022.

6. Wang Z, Wu JH, Li CP, Lv A, Qiu H, Tian XY, Liu BN, Hao CY. Patients with first recurrent retroperitoneal sarcoma that can be macroscopically completely resected can achieve comparable outcomes with that of primary patients after en bloc resection of tumor and adjacent organs. Front Surg. 2022; 9:956384.

7. Wang Z, Wu J, Tian X, Hao C. Targeted therapy of desmoid-type fibromatosis: mechanism, current situation, and future prospects. Front Med. 2019.

8. Lei X, Yan W, Yanan R, Zhen W, Nina Z, Wenyuan Z, Lixin Z, Ling J, Chengxue H, Xiangxi M, Hua Z, Zhi Y. A whole-body imaging technique for tumor-specific diagnostics and screening of B7-H3-targeted therapies. J Clin Invest. 2025.